Esperion to Report Second Quarter 2019 Financial Results August 8, 2019
30 juil. 2019 16h15 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 30, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report second quarter 2019 financial results on August 8, 2019 before the U.S. financial markets...
Esperion and Oberland Capital Announce $200 Million Funding Agreement
26 juin 2019 16h10 HE
|
Esperion Therapeutics, Inc.
- $125 Million Upfront, $25 Million Upon FDA Approval, and $50 Million at Esperion’s Option After Launch -- Initial Mid-Single Digit Repayment Rate on U.S. Revenue to Step Down to Less than One...
Esperion Announces the Appointment of Tracy M. Woody to Board of Directors
30 mai 2019 16h15 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 30, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Tracy M. Woody as a Class I director, with a term expiring at the 2020 meeting of...
Esperion to Participate in Upcoming Investor Conferences
28 mai 2019 07h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 28, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will participate in analyst-led fireside chats with investors at the following conferences:...
Esperion to Participate in Upcoming Investor Conferences
10 mai 2019 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 10, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will participate in analyst-led fireside chats with investors at the following conferences:...
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter Financial Results
08 mai 2019 07h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 08, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the first quarter ended March...
Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review
05 mai 2019 17h00 HE
|
Esperion Therapeutics, Inc.
– Bempedoic Acid is an Oral, Once-daily ATP Citrate Lyase (ACL) Inhibitor that Reduces Cholesterol and Fatty Acid Synthesis in the Liver –– February 21, 2020 PDUFA Target Date Goal for Bempedoic Acid...
Update in Lawsuit for Investors in NASDAQ: ESPR shares against Esperion Therapeutics, Inc. announced by Shareholders Foundation
29 janv. 2019 08h45 HE
|
Shareholders Foundation, Inc.
SAN DIEGO, Jan. 29, 2019 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR). ...
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Esperion Therapeutics, Inc.
10 mai 2018 12h08 HE
|
Federman & Sherwood
OKLAHOMA CITY, May 10, 2018 (GLOBE NEWSWIRE) -- Federman & Sherwood announces that on May 7, 2018, a class action lawsuit was filed in the United States District Court for the District of...
Esperion Announces the Appointment of Jeffrey Berkowitz to Board of Directors
14 déc. 2017 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...